image: The hallmarks of aging, such as mitochondrial dysfunction and telomere attrition, contribute to an increased risk of Alzheimer's disease and other neurological conditions. Rapamycin and other interventions that influence MTOR activity could help delay the progression of these diseases and preserve brain function in the elderly. This material relates to a paper that appeared in the Jan. 23, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by M. Kaeberlein at University of Washington in Seattle, WA; and colleagues was titled, "Rapamycin and Alzheimer's disease: Time for a clinical trial?" view more
Credit: M. Kaeberlein <i>et al., Science Translational Medicine</i> (2018)